Bibliographic record
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised…
Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A. The Lancet Diabetes & Endocrinology 2018
§1Bibliographic record
§1.1Record
- Authors
- Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A
- Title
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- Source
- The Lancet Diabetes & Endocrinology
- Year
- 2018
- Volume, issue, pages
- 6(4):275–286
- Digital object identifier
- 10.1016/S2213-8587(18)30024-X
- PubMed identifier
- 29397376
- Record type
- Journal article
- Institute identifier
- CEI-BR-090
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
| Document | Series |
|---|---|
| Monograph: Dulaglutide | Compound monograph |
| Synthesis: Dulaglutide in type 2 diabetes mellitus: effect on the anchor outcome | Evidence synthesis |
| Synthesis: Dulaglutide in atherosclerotic cardiovascular disease and… | Evidence synthesis |
| Synthesis: Dulaglutide in type 2 diabetes mellitus: tolerability and… | Evidence synthesis |
| Synthesis: Dulaglutide in atherosclerotic cardiovascular disease and… | Evidence synthesis |
| Synthesis: Dulaglutide in type 2 diabetes mellitus: durability of effect | Evidence synthesis |
| 6 citing documents. | |
§1.3Subject tags
semaglutide dulaglutide SUSTAIN
Compound Evidence Institute · CEI-BR-090 · https://compoundevidence.com/bibliography/pratley2018/ · retrieved 30 July 2026